PHLPP2 could be an interesting anti-cancer target in the context of immunochemotherapy, further in vivo studies are needed to confirm whether PHLPP2 inhibition/activation could affect the therapeutic efficacy of immunotherapy in mutant or wild-type p53-driven cancers. This evidence concerns the gene PHLPP2 and cancer.